Part 2 – Epidemiology of inflammatory bowel diseases in the Czech population: available data sources, prevalence of treated patients and overall mortality
EditorialGastroent Hepatol 2019; 73(2): 163–166. doi:10.14735/amgh2019163
pdf Ladislav Dušek, Ondřej Ngo, Ondřej Májek, Jan Mužík, Jakub Kubát, Milan Blaha, Jiří Jarkovský, Milan LukášBiosimilar adalimumab FKB327 (Hulio®)
Drug profileGastroent Hepatol 2019; 73(2) 177–178. doi:10.14735/amgh2019177
Literaturepdf Milan LukášPart 3 – Epidemiology of idiopathic intestinal inflammations in the Czech population – time trends and statistical prediction of the number of patients
Original articleGastroent Hepatol 2019; 73(3): 257–264. doi:10.14735/amgh2019257
Literaturepdf Ladislav Dušek, Klára Benešová, Ondřej Ngo, Ondřej Májek, Jan Mužík, Jakub Kubát, Milan Blaha, Karel Hejduk, Jiří Jarkovský, Milan LukášHeme iron in substitution of sideropenia and sideropenic anemia
Drug profileGastroent Hepatol 2019; 73(3): 271–272. doi:10.14735/amgh2019271
Literaturepdf Milan LukášPart 4 – Mortality and life expectancy in IBD patients
Original articleGastroent Hepatol 2019; 73(4): 345–351. doi:10.14735/amgh2019345
Literaturepdf Ladislav Dušek, Ondřej Májek, Jiří Jarkovský, Klára Benešová, Ondřej Ngo, Jan Mužík, Jakub Kubát, Milan Blaha, Karel Hejduk, Milan LukášTofacitinib – the first JAK inhibitor in the treatment of ulcerative colitis. Beginning of the therapeutic era of „small molecules“ in inflammatory bowel disease?
Drug profileGastroent Hepatol 2019; 73(4): 363–365. doi:10.14735/amgh2019363
Literaturepdf Milan Lukáš